The downregulation of EEF2K was common but not associated with patients’ clinical characteristics (age, gender, tumor location, TNM staging), CRC subtypes (sporadic vs familial) or mutational status (MSI status and mutation of KRAS, BRAF, APC and TP53) (Fig. 5 and Additional file 1). This evidence concerns the gene KRAS and colorectal carcinoma.